ReviewBritish journal of pharmacology2017
Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.
Review in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.European psychiatry : the journal of the Association of European Psychiatrists · 2024Pooled it
- Efficacy of donepezil versus donepezil and trazodone in combination cognitive dysfunction in patients with dementia: a randomized controlled trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Multi-Component Xinjiang Basil Essential Oil Mitigates Alzheimer's Disease-like Pathology Through Amyloid and Neuroinflammatory Modulation.Nutrients · 2026Article
- 2-(Arylamino)thiazol-4(5H)-ones Mitigate Oxidative Stress and Confer Neuroprotection in Cellular andInternational journal of molecular sciences · 2026Article
- Machine Learning and Molecular Modeling Strategy for the Identification of CNS-Active Acetylcholinesterase Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Liraglutide attenuates aluminum chloride-induced Alzheimer's disease in rats by modulating the oxLDL/LPA/LPAR1 pathway.Communications biology · 2026Article
- The cholinergic basal forebrain and its role in neurodegeneration.Journal of neuropathology and experimental neurology · 2025Review
- Monoclonal Antibody Therapies in Alzheimer's Disease: A Guide for Emergency Physicians.Emergency medicine Australasia : EMA · 2025Review
- sc4D: spatio-temporal single-cell transcriptomics analysis through embedded optimal transport identifies joint glial response to Alzheimer's disease pathology.bioRxiv : the preprint server for biology · 2025Article
- Disease-modifying effect of donepezil on APP/PS1 mice at different stages of Alzheimer's disease.Molecular and cellular biochemistry · 2025Article
- Electrochemiluminescence immunoassay using ionic-liquid submicron particles for prostate-specific antigen determination.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Article
- Repurposing Sigma-1 Receptor-Targeting Drugs for Therapeutic Advances in Neurodegenerative Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Understanding the Antidepressant Mechanisms of Acupuncture: Targeting Hippocampal Neuroinflammation, Oxidative Stress, Neuroplasticity, and Apoptosis in CUMS Rats.Molecular neurobiology · 2025Article
- Pathway-based network medicine identifies novel natural products for Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- GENI as an AMPK Activator Binds α and γ Subunits and Improves the Memory Dysfunction of Alzheimer's Disease Mouse Models via Autophagy and Neuroprotection.Antioxidants (Basel, Switzerland) · 2025Article
- Lingguizhugan decoction enhances autophagy of Alzheimer's disease via regulating the mTOR/ p70s6K pathwayFrontiers in aging neuroscience · 2025Article
- Evaluating Blood-Brain Barrier Permeability, Cytotoxicity, and Activity of Potential Acetylcholinesterase Inhibitors: In Vitro and In Silico Study.Pharmacology research & perspectives · 2024Article
- Preparation and application of multiple particle binding-liposomes for electrochemiluminescent signal amplification in bioassays.Analytical and bioanalytical chemistry · 2024Article
- Pharmacologic Treatments for Dementia and the Risk of Developing Age-Related Macular Degeneration.JAMA network open · 2024Article
- Biochemical characterization of chamomile essential oil: Antioxidant, antibacterial, anticancer and neuroprotective activity and potential treatment for Alzheimer's disease.Saudi journal of biological sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is associated with neurodegenerative changes resulting clinically in progressive cognitive and functional deficits. The only therapies are the cholinesterase inhibitors donepezil, galantamine and rivastigmine and the N-methyl-D-aspartate-receptor antagonist memantine. Donepezil acts primarily on the cholinergic system as a symptomatic treatment, but it also has potential for disease modification and may reduce the rate of progression of AD. This review explores the potential for disease modifying effects of donepezil. Several neuroprotective mechanisms that are independent of cholinesterase inhibition, are suggested. Donepezil has demonstrated a range of effects, including protecting against amyloid β, ischaemia and glutamate toxicity; slowing of progression of hippocampal atrophy; and up-regulation of nicotinic acetylcholine receptors. Clinically, early and continuous treatment with donepezil is considered to preserve cognitive function more effectively than delayed treatment. The possible neuroprotective effects of donepezil and the potential for disease pathway modification highlight the importance of early diagnosis and treatment initiation in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.